Study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC using our anti-RAI2 polyclonal antibody
April, 2021 (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan)
Low retinoic acid-induced 2 (RAI2) expression was considered a marker of poor prognosis in breast cancer as of today.
Now, using our anti-RAI2 polyclonal antibody (HPA051054), a new study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC.
The results suggest that RAI2 has a role in the metastasis of breast cancer and that RAI2 expression could actually be used as a promising candidate biomarker of prognosis in breast cancer patients.